BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 33358116)

  • 1. PD1 expression and correlation with its ligands in oral cancer specimens and peripheral blood.
    Wehrhan F; Weber M; Baran C; Agaimy A; Büttner-Herold M; Kesting M; Ries J
    J Craniomaxillofac Surg; 2021 Feb; 49(2):118-125. PubMed ID: 33358116
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic significance of PD-L2 expression in patients with oral squamous cell carcinoma-A comparison to the PD-L1 expression profile.
    Weber M; Wehrhan F; Baran C; Agaimy A; Büttner-Herold M; Kesting M; Ries J
    Cancer Med; 2019 Mar; 8(3):1124-1134. PubMed ID: 30659749
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PD-L1 expression in tumor tissue and peripheral blood of patients with oral squamous cell carcinoma.
    Weber M; Wehrhan F; Baran C; Agaimy A; Büttner-Herold M; Preidl R; Neukam FW; Ries J
    Oncotarget; 2017 Dec; 8(68):112584-112597. PubMed ID: 29348848
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Immune Checkpoint Receptor CD96: A Local and Systemic Immune Modulator in Oral Cancer?
    Trumet L; Weber M; Hahn A; Kunater L; Geppert C; Glajzer J; Struckmeier AK; Möst T; Lutz R; Kesting M; Ries J
    Cancers (Basel); 2023 Apr; 15(7):. PubMed ID: 37046787
    [No Abstract]   [Full Text] [Related]  

  • 5. Cisplatin-induced programmed cell death ligand-2 expression is associated with metastasis ability in oral squamous cell carcinoma.
    Sudo S; Kajiya H; Okano S; Sasaki M; Katsumata Y; Ohno J; Ikebe T; Hiraki A; Okabe K
    Cancer Sci; 2020 Apr; 111(4):1113-1123. PubMed ID: 32012401
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of a Favorable Prognostic Subgroup in Oral Squamous Cell Carcinoma: Characterization of ITGB4/PD-L1
    Ma SR; Liu JF; Jia R; Deng WW; Jia J
    Biomolecules; 2023 Jun; 13(6):. PubMed ID: 37371594
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential expression of programmed death-1 and its ligand, programmed death ligand-1 in oral squamous cell carcinoma with and without oral submucous fibrosis.
    Quan H; Liu S; Shan Z; Liu Z; Chen T; Hu Y; Yao Z; Fang L
    Arch Oral Biol; 2020 Nov; 119():104916. PubMed ID: 32977151
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of immunoregulatory molecules PD-L1 and PD-1 in oral cancer and precancerous lesions: A cohort study of Japanese patients.
    Kouketsu A; Sato I; Oikawa M; Shimizu Y; Saito H; Takahashi T; Kumamoto H
    J Craniomaxillofac Surg; 2019 Jan; 47(1):33-40. PubMed ID: 30466788
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Upregulation of PD-L1 and PD-L2 in neck node metastases of head and neck squamous cell carcinoma.
    Moratin J; Metzger K; Safaltin A; Herpel E; Hoffmann J; Freier K; Hess J; Horn D
    Head Neck; 2019 Aug; 41(8):2484-2491. PubMed ID: 30821864
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PD-L1 Expression in Tumor Cells Is an Independent Unfavorable Prognostic Factor in Oral Squamous Cell Carcinoma.
    de Vicente JC; Rodríguez-Santamarta T; Rodrigo JP; Blanco-Lorenzo V; Allonca E; García-Pedrero JM
    Cancer Epidemiol Biomarkers Prev; 2019 Mar; 28(3):546-554. PubMed ID: 30487133
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of PD-L1 Expression in Oral Squamous Cell Carcinoma and Premalignant Lesions of Oral Cavity.
    Saeed S; Rauf F; Iqbal F; Khan AS; Khan AH; Alamgeer R
    Asian Pac J Cancer Prev; 2022 Dec; 23(12):4039-4045. PubMed ID: 36579984
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is There Evidence for the Presence and Relevance of the PD-1/PD-L1 Pathway in Oral Squamous Cell Carcinoma? Hints From an Immunohistochemical Study.
    Troeltzsch M; Woodlock T; Pianka A; Otto S; Troeltzsch M; Ehrenfeld M; Knösel T
    J Oral Maxillofac Surg; 2017 May; 75(5):969-977. PubMed ID: 27916470
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhanced programmed death 1 (PD-1) and PD-1 ligand (PD-L1) expression in patients with actinic cheilitis and oral squamous cell carcinoma.
    Malaspina TS; Gasparoto TH; Costa MR; de Melo EF; Ikoma MR; Damante JH; Cavassani KA; Garlet GP; da Silva JS; Campanelli AP
    Cancer Immunol Immunother; 2011 Jul; 60(7):965-74. PubMed ID: 21442435
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Programmed cell death protein 1 and its ligands regulate immune balance in allergic rhinitis].
    Wen SL; Li F; Zhao F; Zuo JJ; Deng YQ; Zhang W; Tao ZZ
    Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2020 Apr; 55(4):384-390. PubMed ID: 32306637
    [No Abstract]   [Full Text] [Related]  

  • 15. Significant association of increased PD-L1 and PD-1 expression with nodal metastasis and a poor prognosis in oral squamous cell carcinoma.
    Maruse Y; Kawano S; Jinno T; Matsubara R; Goto Y; Kaneko N; Sakamoto T; Hashiguchi Y; Moriyama M; Toyoshima T; Kitamura R; Tanaka H; Oobu K; Kiyoshima T; Nakamura S
    Int J Oral Maxillofac Surg; 2018 Jul; 47(7):836-845. PubMed ID: 29395669
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation of PD-1 and PD-L1 expression in oral leukoplakia and oral squamous cell carcinoma: an immunohistochemical study.
    Greeshma LR; Joseph AP; Sivakumar TT; Raghavan Pillai V; Vijayakumar G
    Sci Rep; 2023 Dec; 13(1):21698. PubMed ID: 38066025
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune-Related Gene Expression Profiling After PD-1 Blockade in Non-Small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma, and Melanoma.
    Prat A; Navarro A; Paré L; Reguart N; Galván P; Pascual T; Martínez A; Nuciforo P; Comerma L; Alos L; Pardo N; Cedrés S; Fan C; Parker JS; Gaba L; Victoria I; Viñolas N; Vivancos A; Arance A; Felip E
    Cancer Res; 2017 Jul; 77(13):3540-3550. PubMed ID: 28487385
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Programmed cell death-ligand 1 expression in oral squamous cell carcinoma is associated with an inflammatory phenotype.
    Satgunaseelan L; Gupta R; Madore J; Chia N; Lum T; Palme CE; Boyer M; Scolyer RA; Clark JR
    Pathology; 2016 Oct; 48(6):574-80. PubMed ID: 27590194
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The immune microenvironment of HPV-negative oral squamous cell carcinoma from never-smokers and never-drinkers patients suggests higher clinical benefit of IDO1 and PD1/PD-L1 blockade.
    Foy JP; Bertolus C; Michallet MC; Deneuve S; Incitti R; Bendriss-Vermare N; Albaret MA; Ortiz-Cuaran S; Thomas E; Colombe A; Py C; Gadot N; Michot JP; Fayette J; Viari A; Van den Eynde B; Goudot P; Devouassoux-Shisheboran M; Puisieux A; Caux C; Zrounba P; Lantuejoul S; Saintigny P
    Ann Oncol; 2017 Aug; 28(8):1934-1941. PubMed ID: 28460011
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of programmed cell death-ligand 1 in oral squamous cell carcinoma and oral leukoplakia is associated with disease progress and CD8+ tumor-infiltrating lymphocytes.
    Chen XJ; Tan YQ; Zhang N; He MJ; Zhou G
    Pathol Res Pract; 2019 Jun; 215(6):152418. PubMed ID: 31027907
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.